Actuate Therapeutics, Inc. Current Income Tax Expense (Benefit)
Actuate Therapeutics, Inc. (ACTU) reported Current Income Tax Expense (Benefit) of $800 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-26
- Actuate Therapeutics, Inc. current income tax expense (benefit) for fiscal 2025 was $800.00, a 0.00% change from fiscal 2024.
- Actuate Therapeutics, Inc. current income tax expense (benefit) for fiscal 2024 was $800.00.
- Actuate Therapeutics, Inc. current income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $800.00 10-K · filed 2026-03-26 |
| 2024-12-31 | $800.00 10-K · filed 2026-03-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |